Special Issue

Translational Studies of Obesity-Associated Hepatocellular Cancer

Message from the Guest Editors

Hepatocellular Carcinoma (HCC) is the most prevalent form of primary liver cancer, and is among the leading causes of cancer-related deaths around the world. With a 5 year survival rate of less than 15%, HCC is etiologically associated with viral hepatitis, alcohol excess, other hepatotoxins, and metabolic disorders including obesity and type 2 diabetes mellitus (T2DM). While hepatitis and hepatotoxins remain significant causes of HCC, its increasing incidence in many countries is associated with expansion of the obesity pandemic. HCC has been designated an obesityassociated cancer, particularly in men. This Special Issue of Cancers will focus on translational aspects of obesity-associated HCC across the spectrum, from mechanisms and prevention to diagnosis and therapeutics. Articles are invited that study obesityassociated metabolic, immunologic, inflammatory, pathologic, microbiologic, genetic, and molecular alterations that impact obesity-associated HCC as well as their therapeutic implications.

Guest Editors

Prof. Dr. Nathan A. Berger

Department of Medicine, Biochemistry, Oncology, Genetics & Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA

Dr. J. Mark Brown

Department of Cardiovascular & Metabolic Sciences, Center for Microbiome & Human Health, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio 44195, USA

Deadline for manuscript submissions

closed (31 March 2021)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/55384

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

